Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma

Figure 4

Predictions of the immunotherapy markers and sensitivity of chemotherapy drugs in high-risk group and low-risk group of UCS patients. (a–f) The violin plots present the expression of 6 principal immune checkpoint molecules, namely, PDL1, PDL2, CTLA4, CD80, CD86, and PD1 in the TCGA cohort. (g–k) Box plots for the estimated IC50 of chemotherapy drugs between two subtypes, imatinib, cisplatin, docetaxel, doxorubicin, and gemcitabine in the ICGC cohort, respectively.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)